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1. Introduction  
Malignant primary brain tumors exhibit high proliferation index and have the potential for 
local or distant dissemination. GBM is an example of this group of tumor. GBM is a World 
Health Organization (WHO) grade IV tumor. It represents 65% of all gliomas and 15-20% of 
all primary intracranial tumors (Louis et al., 2007). It is the most malignant astrocytic tumor, 
with histolopathological features of cellular polymorphism, high mitotic activity, 
microvascular proliferation, and necrosis (Louis et al., 2007). Despite advances in imaging 
techniques and multimodal treatment options, the overall prognosis of patients with GBM 
remains poor. In a large retrospective study, 2.2% of the cohort resulted in longer than 2-
year survival (Scott et al., 1998). The median survival is between 12-18 months with maximal 
treatment. With medical advancements in the past five years, there is a slight improvement 
in the median survival of these patients; It is estimated that about 24% of patients who 
underwent gross total resection followed by adjuvant chemotherapy and radiation therapy 
will survive 24 months, while those without any intervention succumb rapidly from time of 
diagnosis (Davis et al., 1998; McLendon and Halperin, 2003). Very few cases of curative 
outcome or long term survival have been reported (Salvati et al., 1998; Yoshida et al., 2000). 
Overall, the 5-year survival rate is less than 10% with a final mortality rate of near 100% 
(Deen et al., 1993; Kleihues and Sobin, 2000). 
GBM carries an unfavorable prognosis mainly due to its high propensity for tumor 
recurrence. It has been suggested that GBM recurrence is inevitable after a median survival 
time of 32-36 weeks (Ammirati et al., 1987; Choucair et al., 1986). The natural history of 
recurrent GBM (rGBM), however, is largely undefined due to the lack of uniform definition 
and criteria for tumor recurrence, the variability in treatment philosophy among treating 
physicians, and the heterogeneous nature of the disease, including distinct mechanisms 
believed to contribute to known subtypes of GBM. In this chapter, we have summarized the 
definition of recurrent GBM and provide an overview on the pathophysiology, the 
diagnostic pathways, and treatment algorithm of this disease. We have also included a brief 
synopsis on the future direction in the management and the experimental target-therapies of 
this disease. 
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2. Definition  
Tumor recurrence is defined as the growth of tumor after treatment. However, the criteria 
used to diagnose rGBM remain ambiguous due to the variety in which new lesions present. 
The infiltrative nature of GBM cells makes it difficult to eliminate microscopic disease 
despite macroscopic gross total resection. Studies have shown that GBM recurrence most 
often occurs in the form of a local continuous growth within 2-3 cm from the border of the 
original lesion (Gaspar et al., 1992; Halperin et al., 1988; Lee et al., 1999). Choucair et al. 
reported that over 90% of glioma cases showed recurrence at the original tumor location, 
while 5% developed multiple lesions after treatment (Choucair et al., 1986). Although less 
common (≈10%), GBM may also recur with the development of new lesions that have little 
evidence of being contiguous with previous resection cavity, intraventricular spread, or 
dissemination along any anatomically definable subcortical white matter tracts (Loeffler et 
al., 1990). Bauman et al. has shown that uncommon relapse patterns are more prevalent in 
midline tumors and tumors that infiltrate both hemispheres (Bauman et al., 1998). Likewise, 
in an attempt to preserve neurological function and maintain patient quality of life, subtotal 
resections are sometimes performed when tumors infiltrate eloquent areas of the brain. In 
those circumstances, the residual tumor is treated with focal radiation in addition to 
conventional radiation therapy and chemotherapy. Tumor recurrence is, therefore defined 
by the appearance of residual tumor growth on imaging studies or the manifestation of new 
clinical symptoms. However, tumor recurrence is frequently used synonymously with 
tumor progression. Recurrent GBM is commonly referred as a change from previously 
documented stable tumor or an absence of tumor; it is an escape from prior tumor control. 
Certain authors define tumor progression from a residual tumor as a 25% increase in cross-
sectional area of the tumor in the slice with the greatest amount of tumor or as a 25% 
increase in contrast enhancing volume (Suh and Olson, 1998 ), while recurrence has also 
been defined by a greater than 50% growth between two successive imaging studies (Barker 
et al., 1998). Setting aside the difference in the definition of rGBM, the “local” recurrence 
remains the single most striking common factor among all the patients whom have received 
a variety of chemotherapeutic agents, with different radiation dose and field volume, in 
addition to the extend of resection of the initial tumor. This suggests that the recurrence of 
GBM is intrinsic and independent to the choice of therapy.  
3. The pathophysiology of tumor recurrence 
Neural stem cell surface antigen CD133 has been used to prospectively isolate and 
characterize a rare population of cells within the tumor mass of GBM. This population of 
cells has a striking similarity to normal neural stem cells in its biology (Singh et al., 2004). 
Expansion of these cancer stem cells (CSC) replenishes the cells that constitute the 
expanding cells within the tumor. As these growing cells mature, they undergo terminal 
differentiation. It has been shown that there are at least two populations of cells in GBM 
specimens. They are the CD133+/telomeraseHigh which are presumed to be CSC and CD133- 
/telomeraseLow progenitor cells. There is general consensus that CD133+/telomeraseHigh CSC 
gives rise to CD133- /telomeraseLow progenitor cells. It is the proliferation of these 
progenitor cells that populate and makes up the tumor mass (Beier et al., 2011). Moreover, it 
has been shown that differentiated tumor cells are more susceptible to chemotherapy and 
radiation treatment, and are eliminated from the tumor mass. Additionally, terminally 
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differentiated tumor cells will eventually die off by initiating cell death cascades and there is 
accumulation of CD133+ glioma cells following high-dose irradiation by Gamma Knife 
surgery (GKS) plus external beam radiation (Tamura et al., 2010). Similarly, there is an 
accumulation of CD133+ glioma cells, in residual tumors particularly within the necrotic 
areas after GKS plus EBRT treatment, whereas CD133+ cells are infrequent in tumors prior to 
therapy. It is postulated that the longevity of cancer stem cells and their resilience to 
therapies, give them the ability to serve as the reservoir for regeneration of the whole tumor, 
which provides a plausible explanation for the recurrence of GBM (Liu et al., 2009). 
Additionally, CD133+ cancer stem cells have a higher expression of BCRP1 and MGMT. The 
presence of anti-apoptosis protein and inhibitors of apoptosis protein families explain their 
ability to withstand chemotherapy (Liu et al., 2006). 
An emerging hypothesis states that CSCs drive tumorigenesis by directly inducing an 
inflammatory phenotype within the tumor and facilitate immuno-editing. This occurs by 
recruiting immunocytes and promoting stromal remodeling as seen in aberrant stem cell–
vascular niche that contributes to myeloproliferative diseases (Walkley et al., 2007). In 
response to tumor-derived cytokines, these macrophages acquire the M2 phenotype (Stout 
et al., 2005). Macrophages are a potent source of the mediators that perpetuate the 
inflammatory process, and they release reactive oxygen and nitrogen species. ROS have also 
been shown to modify the activity of myeloid-derived suppressor cells (MDSCs). These cells 
inhibit anti-tumor immunity thus promoting tumors. In combination with nitric oxide, 
MDSC-derived ROS contribute to the generation of peroxynitrite (Nagaraj and Gabrilovich, 
2007). The latter causes the nitration of various proteins on Tyrosine, including the T-cell 
receptor CD8. This modification alters antigen recognition and thereby induces T-cell 
tolerance (Movahedi et al., 2008). Moreover, MDSCs are directly involved in tumor 
angiogenesis, they stimulate angiogenesis and ECM breakdown through the production of 
angiogenic growth factors and MMPs. Secretion of MMPs and other proteinases by 
macrophages enhance cancer-cell motility, dispersion and invasion. Collectively, CSCs 
promote expansion of tumor mass, invasion, and revival of senescence cells.  
4. The clinical profile of patients with recurrent glioblastomas 
The patients with rGBM tend to be male with a reasonable Karnofsky Performance Score 
(KPS) and in age group of 50 to 60. This skewed epidemiological profile can easily be the 
reflection of the variability of treatment algorithms and patients selection employed at 
different institutions. In a multi-center trial of 222 patients with rGBM for evaluation of 
intra-operative placement of biodegradable wafer, the patient cohort was predominantly 
male (64.5%) in the fifth decade of life (48 years old). (Brem et al., 1995). Among a cohort of 
301 GBM patients, Barker et al. identified 223 patients with tumor recurrence (Barker et al., 
1998). Without selection bias, 64% of patients had a KPS >70 at time of recurrence. These 
predominantly male patients (63%) had a mean age of 54 years. The median interval from 
initial diagnosis until clinical or radiographic evidence of tumor recurrence was 4.9 months. 
In majority of the patients, GBM recurrence is detected during imaging surveillance or by 
the development of new or recurring symptoms and signs. The single most commonly 
reported symptom is easy fatigue. In a questionnaire-based study, patients with rGBM or 
anaplastic astrocytoma with a KPS >70 self-reported the following symptoms: fatigue, 
uncertainty about the future, motor difficulties, drowsiness, communication difficulties, and 
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headaches (Osoba et al., 2000a). While most symptoms were likely due to tumor recurrence, 
the authors stated that confounding factors such as radiation necrosis and steroid treatments 
may have contributed to generalized fatigue, whereas headache and uncertainty of the 
future may have been nonspecific for brain cancer. Difficulties with motor-sensory function 
and vision may be directly related to mass effect or edema. 
The most commonly encountered dilemma in diagnosing rGBM is the uncertainty in 
differentiating real tumor progression from that of pseudo-progression/radiation necrosis at 
and around the previously treated site. Pseudo-progression is defined as progressive 
contrast enhancement in imaging study within the first three months (in 58% of the cases) of 
finishing treatment. Patients with pseudo-progression can be symptomatic but are highly 
responsive to steroid therapy. They account for 28-51% of the cases, and 9-14% of these 
patients will eventually show stable disease or resolution. The true mechanism of 
pseudoprogression is unclear. It is thought to be an exacerbated response to effective 
therapy (Chamberlain, 2008; Chamberlain et al., 2007; de Wit et al., 2004). Conversely, 
radiation is toxic to both rapid dividing tumor and the surrounding endothelium and 
oligodendroglial cells. This will result in demyelinating and coagulopathic necrotizing 
reaction 4-6 months after treatment. Importantly, radiation necrosis can mimic rGBM with 
its contrast enhancement, progression, and edema.  
Radiation necrosis versus progression of gliomas can be positively differentiated in biopsy 
specimens. Should a biopsy be non-feasible, imaging becomes the next best option for 
evaluation. Positron Emission Tomography (PET) is not used for initial diagnosis of GBM 
due to relatively inferior image resolution compared to MRI. Rather [18F] 
fluorodeoxyglucose (FDG)-PET is used to demonstrate increased regional glucose 
metabolism, which has been shown to correlate with tumor cellularity and patient survival 
(Ishikawa et al., 1993). In a study evaluating surgical outcomes of rGBM, Barker et al. 
included four patients whose PET suggested proliferation despite an MRI indication of a 
<50% increase in size of residual tumor (Barker et al., 1998). It is particularly useful in the 
early detection of rGBM in cases with unclear MRI information. While radiation necrosis 
mimics tumor recurrence on MRI, it is readily detectable with PET due to its low metabolic 
characteristics. Therefore, PET imaging plays an important role in the management of 
irradiated patients who develop new lesions or symptoms (Ishikawa et al., 1993). PET 
imaging has a specificity of >90% in distinguishing radiation necrosis from rGBM, however, 
it lacks the sensitivity to make it reliable (Thompson et al., 1999). The use of amino acid 
tracers such as [11C]methionine and [18F] tyrosine is shown to improve the sensitivity 
especially, when MRI-PET is used (Thiel et al., 2000). 
The use of serial proton magnetic resonance spectroscopy (MRS) is becoming a standard 
protocol in the imaging rGBMs. This imaging technique, which can append current 
conventional MR imaging protocols, allows serial monitoring of tumor progression. With 
the ability to characterize abnormal processes based on their metabolic signature, It has 
shown that MRS can be used to discriminate between localized radiation necrosis and 
recurrent tumor possessing elevated choline levels after brachytherapy (Wald et al., 1997) 
(See Table 1). In a recent study of 29 patients, Weybright et al. found that both tumor 
recurrence and radiation necrosis demonstrated increased Cho:Cr ratio, Cho/NAA ratio, 
and decreased NAA/Cr when compare to normal brain (Weybright et al., 1998). However, 
the changes appear significantly greater when comparing tumor recurrence and radiation 
necrosis (Cho/Cr: 2.52 vs 1.57; Cho/NAA: 3.48 vs 1.31; NAA/Cr: 0.79 vs 1.22). Similarly, 
Rock et. al. were able to correctly predict the histopathology of the subsequently resected 
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specimen in the case of pure radiation necrosis or pure tumor recurrence (Rock et al., 2002). 
However, it was noted that in specimens with mixed necrosis and neoplasm, the spectral 
patterns were less definitive. Histologically, radiation injury is characterized by damage to 
the vascular endothelium that may result in ischemia and necrosis. In those circumstances 
one will expect an elevated lactate reflecting severe tissue ischemia and a severely depressed 
levels of NAA, choline, and creatine. In addition, radiation necrosis shows a broad peak 
between 0 and 2 ppm corresponding to cellular breakdown products and probably 
consisting of free fatty acids, and amino acids; whereas, in tumor recurrence one will find an 
elevated choline/NAA, elevated choline/creatine, and the presence of lactate. 
Unfortunately, within the same mass, there may be areas of radiation necrosis in 
combination with areas of viable tumor, reducing the specificity of MR spectroscopy. Thus, 
while MRS can be a practical noninvasive screening technique, certain limitations exist at 
this time. 
 
 
MRI  
(w/ gadolinium) 
MRS MR Perfusion PET 
Tumor Hyperintense 
↑↑ Cho / NAA 
↑↑ Ch / Cr 
↓↓ NAA / Cr 
↑ rCBV (>2.6) 
↑ Enhancement rate 
(dI/dt) 
↑ Metabolic activity 
(↑ glucose uptake) 
Radiation 
Necrosis 
Hypointense 
↑ Cho / NAA 
↑ Ch / Cr 
↓ NAA / Cr 
↓ rCBV (<0.6) 
↓ Enhancement rate 
(dI/dt) 
↓ Metabolic activity 
(↓ glucose uptake) 
Table 1. The Characteristic of Tumor and Radiation Necrosis in MRI and PET imaging 
studies. 
Magnetic Resonance Perfusion (MRP) has recently been used to assess tissue vascular 
physiology and to distinguish the recurrence of tumors from radiation necrosis, especially 
with current interest in antiangiogenic therapy for the treatment of GBM. Contrast-
enhancing T2-weighted echo-planar imaging has been evaluated for use in determining 
treatment response of recurrent malignant gliomas, specifically to thalidomide and 
carboplatin and to identify radiation necrosis (Cha et al., 2000). In general, radiation necrosis 
typically shows decreased relative cerebral blood volume (rCBV), whereas tumor recurrence 
results in high rCBV (Aronen and Perkio, 2002). For example, using gradient-echo dynamic 
susceptibility perfusion MR imaging, Sugahara et al found that lesions with rCBV greater 
than 2.6 was indicative of tumor recurrence, while rCBV of less than 0.6 was consistent with 
radiation necrosis (Sugahara et al., 2000). However, there was significant overlap between 
the groups, requiring other modalities such as PET or single photon emission computed 
tomography (SPECT) to allow differentiation. Using more delayed, T1-weighted MR 
permeability methods, Hazle et al. reliably distinguished between tumor recurrence, 
www.intechopen.com
 
Molecular Targets of CNS Tumors 
 
84
radiation necrosis, or a combination of both factors, using an empiric model to study the rate 
of contrast enhancement (Hazle et al., 1997). In this study of 95 patients, the authors found 
that radiation necrosis and glioma tissue enhance at different rates, with recurrent tumors 
having the greatest mean maximal enhancement rates, mixed radiation necrosis and tumor 
having intermediate rate, and pure tumor necrosis having slowest rate.  
5. Treatment options 
With treatment options for rGBM relatively limited, physicians, patients and the patients’ 
families have to be realistic with their therapeutic goals. The primary goal is palliative rather 
than curative. The ultimate aim is to preserve or restore neurological function to allow and 
prolong patients’ comfort, independency, dignity and improved quality of life. The 
Canadian GBM recommendation committee’s practical guideline-2007 addresses the issue of 
recurrent GBM and provides a relatively clear directive for practicing physicians. It states 
“Selected patients with recurrent GBM may be candidates for repeat resection when the 
situation appears favorable based on an assessment of individual patient factors such as 
medical history, functional status, and location of the tumor. Entry into a clinical trial is 
recommended for patients with recurrent disease” (Mason et al., 2007). It essentially stating 
that aggressive treatment should only be entertained if there is (1) reasonable chance to 
prolong meaningful survival and (2) there is “follow-up” experimental or salvaging 
treatment. Other than that, no aggressive treatment such as surgery or radiosurgery should 
be considered.  
Surgical intervention is essential in the initial treatment of GBM. It is well documented that 
the extent of surgery, ranging from biopsy to subtotal resection to gross total resection can 
effect overall patient survival (Black, 1991a, b; Chamberlain and Kormanik, 1998; Mahaley et 
al., 1989). Gross total resection can double median survival as compared to just having a 
biopsy, and in some study gross total resection has a significant survival advantage as 
compared to subtotal or partial resection (80, 48, and 44 weeks respectively) (Nitta and Sato, 
1995). When faced with evidence of rGBM, surgical intervention requires clear identification 
of short-term goals and a diligent consideration of overall prognosis including potential 
treatment side effects. In patients without medical contraindications, surgery can confirm 
tumor recurrence, reduce intracranial pressure, improve neurological status, and possibly 
improve efficacy of adjunctive therapy.  
In patients with low KPS score and/or other co-morbidity, stereotactic biopsy is particularly 
relevant in making management decisions and potentially can expand treatment options 
especially when imaging studies fail to differentiate between radiation necrosis and tumor 
recurrence. Stereotactic approach allows for the sampling of small, inaccessible, or even 
multiple lesions with minimal morbidity and mortality (estimated to be 2-5% and <1% 
respectively) (Suh and Olson, 1998 ). Stereotactic aspiration of tumor-associated cyst may 
offer short-term relief to patient symptoms secondary to mass effect. While uncommonly 
used, chemotherapy or radioactive agents for interstitial brachytherapy may also be 
introduced. Although stereotactic biopsy is frequently performed with relatively low risk, 
clinicians must be aware of potential complications associated with small sampling. 
Multiple-pass sampling may improve overall sensitivity but must be weighed against the 
increased risk of hemorrhage.  
The efficacy and utility of re-resection alone in rGBM remains controversial due to a lack of 
randomized clinical trials evaluating this intervention independently. The majority of 
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studies are confounded by the inherit selection bias to perform surgery on patients with 
high functional status, favorable anatomical locations, and lack of medical contraindications. 
The potential variability in the extent of surgical resection combined with the absence of 
uniform treatments for the initial disease render randomized control studies impractical. 
Despite these limitations, several studies in the literature provide anecdotal evidence and 
justification for re-resection in a select subset of patients with rGBM.  
Prior redo-craniotomy studies, have showed the median survival time after surgical 
resection to be 14-50 weeks (Ammirati et al., 1987; Barker et al., 1998; Brem et al., 1995; 
Nieder et al., 2000; Sipos et al., 1997; Subach et al., 1999). The median survival from the time 
of initial GBM diagnosis among these patients was 13-22 months (Nieder et al., 2000). 
Rostomily et al. reported a prolonged progression-free survival of 7 weeks in patients 
undergoing combined chemotherapy plus re-resection versus chemotherapy alone (21 vs. 14 
weeks) (Rostomily et al., 1994). However, the overall survival among this cohort of 51 
patients was equivocal.  Barker et al. performed a retrospective review of 222 patients with 
rGBM. In this study, the 46 patients who underwent secondary surgery and adjunctive 
therapy demonstrated a median survival time of 36 weeks post-resection (Barker et al., 
1998). In comparison, patients who received similar chemotherapy and/or radiation had a 
median survival time of 23 wks. Interestingly, 28% of patients in the re-resection group had 
an improved KPS, while 49% had similar functional status. The authors noted that while the 
results were likely secondary to selection bias, subset of patients with rGBM might 
potentially benefit from surgical re-resection.  
In addition to decreasing mass effect, redo-craniotomy allows for the potential 
administration of in situ delivery of chemotherapy or brachytherapy. In a randomized study 
evaluating the efficacy of Carmustine (BCNU) implantation during re-resection versus 
placebo, Brem et al. reported a 50% improvement in survival at 6 months following 
treatment (56% vs. 36%) (Brem et al., 1995). In this study, commonly discussed side effects 
such as serious intracranial infections (2.2%), post operative seizures, and steroid 
requirements for edema were reported to be within accepted ranges for redo surgery alone. 
The consensus belief that remains that the morbidity is higher in re-operation and wound 
dehiscence is relative common (5-18%).  
Overall, surgical resection in rGBM may provide a modest benefit in survival (extends 
median survival by 36 weeks) and/or improvement in quality of life (10 weeks of high 
quality survival when the pre-operative KPS is > 70) within a subset of patients. Brem et al. 
showed that pre-operative performance status and age were significant prognostic factors 
(Brem et al., 1995). Similarly, in a multivariate analysis by Ammirati et al, performance 
status was found to be a significant predictor of outcome, however patient age appeared to 
be noncontributory (Ammirati et al., 1987). The extent of initial resection has also been 
shown to influence patient survival (Durmaz et al., 1997). While minor discrepancies exist 
among different studies, the general consensus is that surgical resection should be seriously 
considered in those with a high KPS (>70) and whose lesions are in a favorable location. 
Similarly, the time from the initial resection to clinical recurrence is also a useful 
prognosticator for re-operation. 
6. Chemotherapy 
Chemotherapy remains the main component in the salvage treatment of recurrent malignant 
gliomas (Chamberlain and Kormanik, 1998; Combs et al., 2005). Chemotherapeutic agents 
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such as temozolomide (TMZ), carboplatin, procarabzine (PCB), Bevacizumab, irinotecan, 
and imatinib mesylate are currently been used in a variety of schema to treat rGBMs (Osoba 
et al., 2000b). These drugs have been administered as a single-agent, multi-agent, interstitial, 
intrathecal and combinatorial therapies, and are hypothesized to decrease the risk of death 
by approximately 15% (Stewart, 2002). In this study the 2-year survival for individuals with 
GBM increased from 9% to 13% when chemotherapy was used. 
The treatment of rGBM tumors with TMZ is promising and with a favorable toxicity 
profile. One has to differentiate between treatment failure and escape. Most of the patients 
with rGBM are relapsed from remission. In a study by Brandes et al., patients who were 
treated for recurrent or progressive GBM with a TMZ chemotherapy regimen showed an 
overall response rate of 19% and mean time to progression of 11.7 wks (Brandes et al., 
2002). Similarly, it was found that treatment of rGBM with a standard TMZ regimen (150 
to 200 mg/m2 x 5 days in 28-day cycles) produced a progression free survival of 6 months 
(PFS-6) of 21% vs. another chemo-agent PCB which produced an 8% PFS-6 (Yung et al., 
2000). However, more recent studies have shown that a more rigorous regimen (150 
mg/m2 daily on a week on/week off cycle) may yield a PFS-6 as high as 48% with an 
overall PFS-12 of 81% (Wick et al., 2004). A similar study has shown that PFS-6 as high as 
43.8% with an overall survival (OAS) of 8.4 months.  But when TMZ is used as a five days 
a week cycle, the PFS-6 is noted to be 39% and the OAS is 7.8 weeks. A Various 
combinatorial strategies have been examined including TMZ plus marimastat, a matrix 
metalloproteinase inhibitor, or 13-cis-retinoic acid, resulting in a PFS-6 of 39% and 32%, 
respectively (Jaeckle et al., 2003). 
7. Antiangiogenic treatment  
Increasingly, therapy that is targeting tumor angiogenesis has proven to be effective in 
tumor control and stabilization.  Bevacizumab targets tumor angiogenesis by neutralizing 
VEGF-A. In May 2009, the US food and Drug Aministration (FDA) has granted accelerated 
approval for Bevacizumab for use in patients with rGBM. A noticeable response (26%) with 
a median duration of response is 4.2 months is observed in the AV3708g trial, and a 20% 
response with a median duration of 3.9 months is reported in the NCI 06-C-0064E study, in 
which Bevacizumab is used on its own. However, it has been shown that antiangiogenic 
treatment in the form of monotherapy produces limited clinical effects; and its delayed onset 
allows tumor progression and reduces its use for end-stage disease (O'Reilly, 2006). 
However, the use of antiangiogenics in a combinatorial fashion may provide better results 
(Baumann et al., 2004). Often coupled with a chemotherapy agent, antiangiogenic therapies 
have been shown to be effective in primary GBM tumors producing a survival time of 16 
months (Tuettenberg et al., 2005). Similarly, in determining which chemotherapeutic to use, 
it has been shown that PTK-787 (a VEGF receptor inhibitor) combined with TMZ produced 
a median time to progression of 15.1 wks vs. PTK-787 combined with CCNU which resulted 
in 10.4 wks (Zhang and Chakravarti, 2006). One of the most promising combinations is the 
use of Bevacizumab with irinotecan (CPT-11). With this regimen the PFS-6 and OSA is 50% 
and 8.7 months while with Bevacizumab on its own, the PFS and OAS was 42% and 9.2 
months respectively (Jakobsen et al., 2011). 
In our institute, the choice of salvaging chemotherapy for patients with rGBM is mainly 
based on their past therapeutic history and the toxicity profile. In general, we like to use 
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Bevacizumab, or Bevacizumab/CPT-11 as the first line therapy. It is especially preferred 
when Stereotactic radiosurgery is planned. 
8. Stereotactic radiation and brachytherapy  
Stereotactic radiosurgery (SRS) and hypofractionated radiotherapy are non-invasive 
methods for the delivery of localized irradiation, and have been shown to be effective in 
treating rGBM (Combs et al., 2005; Romanelli et al., 2009). The median survival of patients 
undergoing single fraction SRS therapy (median dose of 15 Gy) for rGBM tumors was 10 
months (Combs et al., 2005). This finding is consistent with several other studies that report 
similar survival times (Mahajan et al., 2005; Shrieve et al., 1995). The risks associated with 
SRS treatment include the possibility of radiation induced necrosis, edema, hydrocephalus, 
worsening of pre-existing symptoms, and radiation toxicity. Specifically, the application of 
SRS to larger tumors has been avoided due to an increased risk of radiation induced toxicity 
and mass effect (Shaw et al., 2000). However, in a recent study hypofractionated stereotactic 
radiosurgery in combination with Bevacizumab resulted in a OAS of 12.5 months, PFS-6 of 
65% and an over all response rate of 50%, along with relatively lower radiation toxicity 
profile.  
The use of brachytherapy has evolved over the last decade. Primarily a treatment for 
rGBM, brachytherapy is associated with an increase in survival time. Interstitial 
brachytherapy is used to target greater radiation doses to tumor cells while limiting 
exposure to surrounding normal brain tissue. Latest brachytherapy techniques report a 
median survival time (post-brachytherapy) for rGBM of 9.1 months, a competitive figure 
when compared to re-resection alone, chemotherapy, or re-irradiation (Chan et al., 2005). 
Similarly, it has also been shown that treatment of rGBM tumors with high-activity 
removable iodine-125 interstitial brain implants elicits a long term (3-year) survival rate of 
15% (Scharfen et al., 1992). 
Unfortunately, the application of brachytherapy is limited. Only 20-30% of rGBM tumors 
meet the morphological and focal criteria necessary for the surgical intervention associated 
with brachytherapy (Salcman, 1994). In some cases, post-treatment reoperation is necessary 
to remove the therapeutic device or to address focal radiation necrosis. Possible 
complications associated with brachytherapy include the development of homonymous 
quadrantanopsia, focal necrosis, edema, and neurological deterioration (Shrieve et al., 1995). 
Nevertheless, the efficacy of brachytherapy treatment is similar to that of SRS. Comparing 
the outcome of patients treated with SRS vs. brachytherapy, there was an overall survival 
time of 10.2 months for SRS treated patients and 11.4 months for brachytherapy treated 
patients (Shrieve et al., 1995). 
9. Novel therapies 
Most of the recent developments in chemotherapy are focus on targeted molecular therapies 
against the epidermal growth factor receptor (EGFR), the mammalian target of rapamycin 
(mTOR), and other signal transduction pathway components. Small-molecule EGFR 
inhibitors such as gefitinib and erlotinib are well tolerated in patients with rGBM, but the 
results from multiple clinical trails are disappointing (Rich et al., 2004; van den Bent et al., 
2009).  
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The use of Temsirolimus, an mTOR inhibitor, as a single agent shows marginal success. 
Combinations of several agents, such as EGFR inhibitors with inhibitors of mTOR and 
VEGF receptors (VEGFR), are now being evaluated. Agents targeting VEGF, VEGFR, and 
other proangiogenic signaling pathways are relatively promising. Cediranib, a small-
molecule inhibitor of VEGFR, shows a response rate of 56% PFS-6 of 26% (Batchelor et al., 
2007; Galanis et al., 2005). AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, 
normalizes tumor vasculature and alleviates edema in GBM patients (Batchelor et al., 2007).  
Sorafenib and sunitinib are FDA-approved TKi that target VEGFR, but they have limited 
activity in rGBM. Although antiangiogenic therapies are promising, the duration of 
response is limited. Other therapeutic approaches such as viral gene therapies, 
immunotherapies, and convection-enhanced delivery of targeted immunotoxins are 
undergoing evaluation, but their use in rGBM remains to be determined (Wen and Brandes, 
2009). 
10. Conclusion 
Patients with GBM continue to have a poor prognosis. In patients who have completed first-
line therapy, vigilant tumor surveillance with regularly scheduled imaging and clinical 
evaluations may enable early detection of tumor recurrence and allow for immediate 
treatments. With the frequent use of radiation therapy, potential radiation induced 
injury/necrosis remains the major nuance in differentiating patients who develop new or 
repeat symptoms due to tumor recurrence. Hopefully, novel imaging techniques can help to 
detect the activation of tumor progression at molecular and cellular levels before 
conventional radiographic changes are seen. But to date we still rely on MRS, MR Perfusion 
and diffusion studies, and PET imaging. 
Limited evidence from randomized studies have shown that among patients determined to 
be favorable surgical candidates (high KPS, non-eloquent location, no medical 
contraindications), the addition of salvaging chemotherapy appears to provide progression 
free survival. TMZ is now the standard chemotherapy agent due to its administrative ease, 
minimal side effect profile and proven survival improvement. Its use is not restricted by 
previous administration. Re-operation should be considered in patients with high 
preoperative KPS or in those whose symptoms are secondary to mass effect from superficial 
non-eloquent regions. The benefits of SRS treatment and chemotherapy are similar and 
should be chosen based on their corresponding side effect profiles. In general, improved 
outcomes are witnessed with combinatorial radiotherapy and chemotherapy as compared to 
each treatment alone.  
Current trends indicate that the treatment of rGBM will remain multimodal in nature. 
Further understanding of underlying tumor biology is essential in developing more 
effective strategies. Research in gene therapy, antiangiogenic antagonists, and 
immunotherapies, all hold great promises. With continual improvements in treatment and 
imaging technique it is the hope of clinicians, researchers, and patients that GBM may 
become a controllable disease with favorable prognosis. Nevertheless, there will be time 
when no further medical and surgical treatments are going to be effective in preserving the 
comfort and dignity of our patients. Then, as clinicians we have to have the insight to 
prepare our patients from the inevitable and address the end-of life issue, and introduce 
them to the expertise of our hospice service.  
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Agent Phase Target 
2ME2 Phase II inhibits HIF-1α 
Cediranib Phase II VEGFR and PDGFR inhibitor 
Enzastaurin Phase II Inhibits Protein Kinase C 
Pazopanib Phase II VEGFR and PDGFR inhibitor 
PTC299 Phase II inhibits VEGF at the post-transcriptionally 
sorafenib Phase I/II VEGFR, PDGFR and BRAF inhibitor 
Sunitinib Phase II VEGFR and PDGFR inhibitor 
Tandutinib Phase II Inhibits PDGFR 
Vandetanib Phase I/II inhibits VEGFR and EGFR 
Vatalanib Phase I/II VEGFR and PDGFR inhibitor 
Vorinostat Phase I Inhibits Histone Deacetylases 
ABT510 Phase II inhibits CD36 receptor 
Aflibercept Phase I/II decoy receptor for VEGF 
ATN161 Phase II peptide inhibits integrin a5ß1 
Bevacizumab Phase II/III monoclonal antibody binds to VEGF 
Cilengitide Phase II/III RGD synthetic peptide inhibits integrin avß3 and avß5 
CT322 Phase I Fibronectin based VEGFR inhibitor 
Interferon Alfa 2b Phase II inhibits angiogenesis 
TM601 Phase I peptide binds to Annexin A2 
The list includes use of agents as isolated or in combination with other dugs. Protein or 
peptide based inhibitors are shaded in grey. 
Table 2. Antiangiogenic agents at various stages of clinical trial for rGBM 
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Neurosurgical treatment interventions are labeled in green. 
 
Clinical evaluations 
and MRI/MRS
New or return of
neurological symptoms
No prior radiation
Suspect radiation necrosis 
equivocal MRS findings
Tumor recurrence 
confirmed
PET to rule out 
radiation necrosis
Confirmed 
radiation necrosis
Equivocal PET 
findings
Stereotactic Biopsy
Steroids and/or 
resection if indicated
Multiple lesions 
Prognosis >3 months
Non-surgical candidate
Radiosurgery with 
Salvaging Chemotherapy
KPS > 70
Favorable location
No contraindication
Re-operation with or
without BCNU/Gliacyte
implantation
Diffuse pathology
Grim prognosis
Poor KPS
Comfort measures and 
introduction to hospices
Adjunctive chemotherapy
and/or radiation
Experimental treatment
 
Fig. 1. Management algorithm of recurrent glioblastoma 
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